Navigation Links
Roche responds to announcement of 'IDEAL' hepatitis C trial results
Date:1/14/2008

ted with HIV before or during treatment. PEGASYS is also contraindicated in neonates and infants because it contains benzyl alcohol. Benzyl alcohol is associated with an increased incidence of neurological and other complications in neonates and infants, which are sometimes fatal. PEGASYS and COPEGUS therapy is additionally contraindicated in patients with a hypersensitivity to COPEGUS or any of its components, in women who are pregnant, men whose female partners are pregnant, and patients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia).

COPEGUS THERAPY SHOULD NOT BE STARTED UNLESS A REPORT OF A NEGATIVE PREGNANCY TEST HAS BEEN OBTAINED IMMEDIATELY PRIOR TO INITIATION OF THERAPY. Women of childbearing potential and men must use two forms of effective contraception during treatment and during the 6 months after treatment has concluded. Routine monthly pregnancy tests must be performed during this time. If pregnancy should occur during treatment or during 6 months post-therapy, the patient must be advised of the significant teratogenic risk of COPEGUS therapy to the fetus. Healthcare providers and patients are strongly encouraged to immediately report any pregnancy in a patient or partner of a patient during treatment or during 6 months after treatment cessation to the Ribavirin Pregnancy Registry at 1-800-593-2214.

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS. During treatment, patients' clinical status and hepatic function should be closely monitored, and PEGASYS treatment should be immediately discontinued if decompensation (Child-Pugh score .6) is observed.

The most common adverse events reported for PEGASYS and COPEGUS combination therapy observed in clinical trials were fatigue/asthenia (65%), headache (43%), pyrexia (41%), myalgia (40%), irritability/anxiety/nervousness (33%), insomnia (30%), alopecia (28%), n
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
2. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
3. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
4. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
9. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
10. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
11. Schering-Plough Reports Top-Line Results of the IDEAL Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 STAAR Surgical Company ... of implantable lenses and delivery systems for the eye, today ... P. Wall to the Company,s Board. ... a Boston -based investment firm, for more ... the Board of Directors, and chair of the Corporate Governance ...
(Date:9/2/2015)... and Markets ( http://www.researchandmarkets.com/research/l8z67c/pharmaceutical ) has announced the addition of ... November 26-27, 2015)" conference to their offering. ... key areas of pharmaceutical regulatory affairs in China ... Macau and Taiwan and ... gaining and maintaining a successful Marketing Authorisation in the region ...
(Date:9/2/2015)... THOUSAND OAKS, Calif. , Sept. 2, 2015 ... announced the submission of a Marketing Authorization Application ... the centralized procedure for etelcalcetide (formerly AMG 416) ... adult patients with chronic kidney disease (CKD) on ... first calcimimetic agent that can be administered intravenously. ...
Breaking Medicine Technology:William P. Wall Appointed to STAAR Surgical Board of Directors 2Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 6Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 7
(Date:9/2/2015)... ... ... an article published August 12 by International Business Times, a new bill was ... juries in cases meant to decide if a police officer used deadly or excessive force ... Ferguson and New York City that absolved police officers of charges in the deaths of ...
(Date:9/2/2015)... ... , ... Date and time: Oct. 3, 2015, 9 a.m. to 4 p.m. ... Bryn Athyn, Pa 19009 , Cost: $50 per person; includes lunch , The Quakertown, ... author Sam Keen based on his new book which he co-authored with his son, ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... announces its latest addition to its screen mirroring and extending product line -- ... Wireless Display, which operates in local WIFI setting, the new Splashtop Wired XDisplay ...
(Date:9/2/2015)... ... September 02, 2015 , ... Michael Elliot Media announces ... a plus-size actress as the primary love interest in the film. The campaign is ... film, significantly affects how and what we think,” Michael Elliot, an award-winning screenwriter and ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... Ericson is ... CDI Education Director for HCPro and Associate Director of Education for the Association for ... Advancing CDI and ICD-10 for CDI Boot Camps. She serves as a CDI subject ...
Breaking Medicine News(10 mins):Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 3Health News:Award-Winning Screenwriter Uses Crowdfunding Campaign to Change Hollywood’s Ideal of Beauty to Include PLUS-SIZE Women 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4
... Exercise is known to have a positive effect on maintaining ... of the Journal of Thoracic Oncology has shown ... and secondary prevention of cancer. The Journal of Thoracic ... for the Study of Lung Cancer. Dr. Jennifer Temel at ...
... for All Michigan Residents Will ... recession sends record numbers of Michigan residents onto the ... health insurance, any mid-year cuts to Medicaid would harm ... hospital executives, long-term-care and mental health providers implored the ...
... Media Plays Major Role in Prompting Parent-Teen Discussions ... Dads Have Opportunity to Engage More with KidsNEW ... survey of parents, attitudes about teen drug and ... Partnership for a Drug-Free America and MetLife Foundation. ...
... -- Dr. Hisao Asamura and his team of researchers at ... records of 2,281 patients who underwent lung cancer resection surgery ... May issue of the Journal of Thoracic Oncology , ... of Lung Cancer. Dr. Asamura and his team found that ...
... NASHVILLE, Tenn., May 4 Healthcare Management Systems, Inc.(R) ... as a hospital information technology provider. HMS has ... top HIT vendors; they currently develop, sell and support ... Over the last decade, HMS has expanded its ...
... A new study on old rats by a Penn State ... heart disease and aging in women. , Heart disease is ... of 75. After menopause, women lose their ability to produce ... somehow make women more vulnerable to heart disease and heart ...
Cached Medicine News:Health News:EO Medicaid Cuts Would Harm People 2Health News:EO Medicaid Cuts Would Harm People 3Health News:National Survey: Parents Report Increased Awareness of Risks of Teen Prescription Drug Abuse, But Preventative Action Lags 2Health News:National Survey: Parents Report Increased Awareness of Risks of Teen Prescription Drug Abuse, But Preventative Action Lags 3Health News:National Survey: Parents Report Increased Awareness of Risks of Teen Prescription Drug Abuse, But Preventative Action Lags 4Health News:National Survey: Parents Report Increased Awareness of Risks of Teen Prescription Drug Abuse, But Preventative Action Lags 5Health News:Healthcare Management Systems Celebrates 25 Years 2Health News:Penn State professor investigates estrogen, heart disease connection in women 2
... Accurately tests for Nystagmus when ... 10" high by 8" diameter. Light ... ball bearings for effortless spin mechanism. ... from patient. Includes both Adult and ...
Diagnose dry eye, assess the effectiveness of permanent punctal occlusion, collagen - dissolvable in 3-5 days, all are 2 mm long. Sterile...
Clear Base Stand Magnifiers are ideal for any visual task that requires high magnification....
Contour design eyelid implants....
Medicine Products: